Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation
Main finding · UTIResult — go to the resultRelative risk 0.98 95% CI 0.95–1.01Authors' conclusion
Initiation of empagliflozin versus dapagliflozin was associated with comparable absolute risks of urogenital adverse events, and slightly higher relative risks of GTI and phimosis among empagliflozin initiators, supporting broadly similar safety profiles.
Study context
- Population
- Adult metformin users with T2D initiating empagliflozin or dapagliflozin, 2015–2022median follow-up 2.6 to 3.8 years
- Participants
- 53,083 vs 33,349
- Exposure
- Empagliflozin vs dapagliflozin initiation
- Empagliflozinn = 53,083
- Dapagliflozinn = 33,349reference
- Outcome
- Risks of urinary tract infection (UTI), genital tract infection (GTI) and phimosis
- Follow-up
- 1-year
Methodological detailsactive-comparator, new-user, inverse probability of treatment weighting
- Active-comparator
- New-user
- Inverse probability of treatment weighting
Main finding
UTI
Relative risk
0.98
95% CI 0.95–1.01
By group
Empagliflozinvs Dapagliflozin
RR 0.98 (95% CI 0.95–1.01)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Empagliflozin | Dapagliflozin | RR (95% CI) | |
|---|---|---|---|---|
| GTI | 2.2% | 2.0% | 1.14 (1.04–1.25) | |
| Phimosis | 1.0% | 0.8% | 1.23 (1.04–1.52) | |
| 0.512Relative risk (log scale) |
Safety
Safety profiles over 5-year follow-up
- Safety profiles were consistent throughout 5-year follow-up
Original publication
Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation. Diabetes Obes Metab. Published 3 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →